137 related articles for article (PubMed ID: 10447584)
1. Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours.
Nannan Panday VR; de Wit R; Schornagel JH; Schot M; Rosing H; Lieverst J; ten Bokkel Huinink WW; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 1999; 44(4):349-53. PubMed ID: 10447584
[TBL] [Abstract][Full Text] [Related]
2. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma.
Gershenson DM; Morris M; Burke TW; Levenback C; Wolf J; Lee JJ; Thall PF; Atkinson EN; Silva EG; Wharton JT
Cancer; 1999 Dec; 86(11):2291-300. PubMed ID: 10590370
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin.
Rowinsky EK; Jiroutek M; Bonomi P; Johnson D; Baker SD
Clin Cancer Res; 1999 Apr; 5(4):767-74. PubMed ID: 10213211
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacologic study of a 3-hour infusion of paclitaxel followed by cisplatinum and 5-fluorouracil in patients with advanced solid tumors.
Bhalla KN; Kumar GN; Walle UK; Ibrado AM; Javed T; Stuart RK; Reed C; Arbuck SG; Walle T
Clin Cancer Res; 1999 Jul; 5(7):1723-30. PubMed ID: 10430075
[TBL] [Abstract][Full Text] [Related]
6. A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors.
Diab SG; Baker SD; Joshi A; Burris HA; Cobb PW; Villalona-Calero MA; Eckhardt SG; Weiss GR; Rodriguez GI; Drengler R; Kraynak M; Hammond L; Finizio M; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1999 Feb; 5(2):299-308. PubMed ID: 10037178
[TBL] [Abstract][Full Text] [Related]
7. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés-Funes H
Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971
[TBL] [Abstract][Full Text] [Related]
8. Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel.
Britten CD; Baker SD; Denis LJ; Johnson T; Drengler R; Siu LL; Duchin K; Kuhn J; Rowinsky EK
Clin Cancer Res; 2000 Sep; 6(9):3459-68. PubMed ID: 10999729
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in patients with solid tumors.
Rocha Lima CM; Catapano CV; Pacheco D; Sherman CA; Oakhill G; Mushtaq C; Freeman KD; Green MR
Cancer; 2004 Jun; 100(12):2671-9. PubMed ID: 15197811
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours.
Kosmas C; Tsavaris NB; Polyzos A; Malamos NA; Katsikas M; Antonopoulos MJ
Br J Cancer; 2000 Jan; 82(2):300-7. PubMed ID: 10646881
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectivenes of paclitaxel plus cisplatin in advanced non-small-cell lung cancer.
Earle CC; Evans WK
Br J Cancer; 1999 May; 80(5-6):815-20. PubMed ID: 10360660
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology Group.
Kelly K; Lovato L; Bunn PA; Livingston RB; Zangmeister J; Taylor SA; Roychowdhury D; Crowley JJ; Gandara DR;
Clin Cancer Res; 2001 Aug; 7(8):2325-9. PubMed ID: 11489808
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer: a University of Colorado Cancer Center study.
Bunn PA; Kelly KL
Semin Oncol; 1995 Oct; 22(5 Suppl 12):54-8; discussion 59-60. PubMed ID: 7481862
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer.
Bunn PA; Kelly K
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-144-S12-148. PubMed ID: 9331140
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of escalating dose of docetaxel administered with granulocyte colony-stimulating factor support in adult advanced solid tumors.
Gonçalves A; Viret F; Ciccolini J; Genre D; Gravis G; Giovanini M; Camerlo J; Catalin J; Maraninchi D; Viens P
Clin Cancer Res; 2003 Jan; 9(1):102-8. PubMed ID: 12538457
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983.
de Wit R; Skoneczna I; Daugaard G; De Santis M; Garin A; Aass N; Witjes AJ; Albers P; White JD; Germa-Lluch JR; Marreaud S; Collette L
J Clin Oncol; 2012 Mar; 30(8):792-9. PubMed ID: 22271474
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
Liu J; Kraut E; Bender J; Brooks R; Balcerzak S; Grever M; Stanley H; D'Ambrosio S; Gibson-D'Ambrosio R; Chan KK
Cancer Chemother Pharmacol; 2002 May; 49(5):367-74. PubMed ID: 11976830
[TBL] [Abstract][Full Text] [Related]
19. Study of escalating doses of paclitaxel plus cisplatin in patients with inoperable head and neck cancer.
Hitt R; Hornedo J; Colomer R; Hidalgo M; Brandariz A; Peña M; Vicent JA; Cortés-Funes H
Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-58-S2-64. PubMed ID: 9045339
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin/etoposide vs paclitaxel/cisplatin/G-CSF vs paclitaxel/cisplatin in non-small-cell lung cancer.
Bonomi P; Kim K; Kusler J; Johnson D
Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):9-10. PubMed ID: 9144683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
